With the acquisition, reported in October, Teva gains Théramex's portfolio of women's health and gynecology products
. Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) said today that it has completed the acquisition of Théramex, which was once Merck KGaA's European-based women's health business.
With the acquisition, reported in October, Teva gains Théramex's portfolio of women's health and gynecology products. The products are sold in over 50 countries, primarily France and Italy. Théramex’s pipeline includes NOMAC/E2, a new oral contraceptive based on natural estrogens, which has successfully completed phase III studies and was submitted for approval in Europe.
Théramex has more than 300 employees in France and Italy.
Teva shares opened down 0.6% on Nasdaq today.
Published by Globes [online], Israel business news - www.globes-online.com - on January 5, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011